Skip to main content

Table 1 Association of patient characteristics with patient-provider discordance in global assessments of disease activity in the total study population

From: Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation

Characteristic All patients
(N = 339)
Concordant group
(n = 236)
Discordant groupa
(n = 103)
P value
Age, years 63.5 (55.1–72.8) 62.4 (55.1–73.8) 63.5 (54.9–72.0) .79
Sex .15
 Female 235 (69) 158 (67) 77 (75)  
 Male 104 (31) 78 (33) 26 (25)  
Disease duration, years 7.0 (2.7, 11.4) 7.4 (3.5, 11.7) 6.3 (2.2, 8.8) .53
Provider type .63
 NP/PA 230 (68) 160 (68) 70 (68)  
 Physician 90 (27) 61 (26) 29 (28)  
 Fellow 19 (6) 15 (6) 4 (4)  
Comorbidity
 Fibromyalgia 28 (8) 10 (4) 18 (17) < .001
 Depression 101 (30) 61 (26) 40 (39) .02
 Osteoarthritis 184 (54) 121 (51) 63 (61) .09
 Sleep apnea 63 (19) 47 (20) 16 (16) .34
 Obesity (BMI ≥ 30 kg/m2) 130 (42) 87 (39) 43 (47) .19
 BMI, kg/m2 28.5 (25.1–33.7) 28.4 (24.2–32.9) 29.4 (26.5–35.4) .03
Disease assessment
 Patient global, 0-100 33 (11–57) 20 (6–44) 57 (46–72) < .001
 Provider global, 0-100 15 (5–30) 15 (5–40) 15 (10–20) .20
 Pain VAS, 0-100 38 (15–63) 24 (9–50) 60 (44–73) < .001
 Tender joint count ≥ 2 121 (36) 75 (32) 46 (45) .02
 Swollen joint count ≥ 2 122 (36) 82 (35) 40 (39) .47
 DAS28-CRP 3.0 (2.2–4.4) 2.6 (1.9–4.1) 3.7 (2.7–4.7) .004
 CDAI 7.5 (3.0–14.5) 5.6 (2.0–13.8) 9.8 (6.5–15.6) < .001
  Remission, < 2.8 80 (24) 78 (33) 2 (2) < .001
  LDA, ≥ 2.8 to < 10.0 130 (38) 79 (33) 51 (50)  
  MDA, ≥ 10.0 to < 22.0 89 (26) 51 (22) 38 (37)  
  HDA, ≥ 22.0 40 (12) 28 (12) 12 (12)  
Laboratory assessment
 CRP, mg/L 3.2 (2.9–9.2) 3.3 (2.9–9.4) 3.2 (2.9–9.2) .96
 RF positivity 233 (71) 173 (75) 60 (61) .01
 Anti-CCP antibody positivity 201 (67) 146 (71) 55 (59) .045
Radiographic joint erosion 172 (52) 133 (57) 39 (39) .002
Medication use
 Prednisone 150 (44) 101 (43) 49 (48) .42
 Methotrexate 215 (63) 148 (63) 67 (65) .68
 Biologics 125 (37) 83 (35) 42 (41) .33
 Change of RA medications at index visit 91 (27) 69 (29) 22 (21) .13
 Opioid 78 (23) 45 (19) 33 (32) .009
 Fibromyalgia med 33 (10) 16 (7) 17 (17) .005
 Sleep aid 36 (11) 18 (8) 18 (17) .007
 Antidepressant or anxiolytic 80 (24) 45 (19) 35 (34) .003
  1. aValues are presented as median (interquartile range) or number (percentage)
  2. bDiscordant group contains only those patients with a global assessment greater than the physician global assessment
  3. anti-CCP anticyclic citrullinated peptide, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP Disease Activity Score in 28 joints using C-reactive protein, DMARD disease-modifying antirheumatic drug, HDA high disease activity, LDA low disease activity, MDA moderate disease activity, NP nurse practitioner, PA physician assistant, RA rheumatoid arthritis, RF rheumatoid factor